Blood carries oxygen which is required for a healthy body functioning. When the concentration of oxygen is reduced in the blood then an oxygen-sensing protein present in the kidney identifies the deficiency of oxygen gradient in the blood and then induces the EPO production,which then turns upon the erythroid cell line in the bone marrow to stimulate hematopoiesis and thus it response to the change in blood oxygen gradient. Endogenous erythropoietin (EPO) is a glycoprotein hematopoietic hormone, which is synthesized, in the renal tubules. EPO helps in controlling and regulating the mechanism of erythropoiesisin the bone marrow. Due to anemia and renal problem, the production of erythropoietin (EPO) istroubled, resulting into fatigue, weakness, shortness of breath, pale skin and insomnia.For treating anemia,chemotherapy induced anemia, renal disorders and others erythropoietin stimulating drugs (EPO) are used.For development of synthetic form of erythropoietin drugs such as epoetin alfa, epoetin beta, darbepoetin alfa, epoetin delta, epoetin omega and others with the help of improved recombinant DNA technology.Recombinant erythropoietin is an artificialformof natural erythropoietin. These are made by cloning the gene for erythropoietin. Among synthetic EPO’sepoetin alfa, epoetin beta, epoetin omega, epoetin delta and darbepoetin-alpha are used extensively. Epoetin delta is another recombinant EPO that is been used for treating patients with chronic kidney disease (CKD).
GlobalErythropoietin stimulating agent market are driven by increasing number of patients suffering from anemia, anemia induced due to cancer, end stage renal disease (ESRD) and HIV treatment. In June 1989,Epoetin alfa was the first drug for EPO, manufactured by Amgen Inc. U.S FDA approved itunder the trade name “Epogen”.The global market for erythropoietin drugs are expected to grow in near future as increased cases of cancer and renal problem haveregistered. With the expiration of Amgen’s patent for Epogen, it has helped the production of other biosimilars EPO drugs. Hence, availability of many biosimilar drugs has renderedlow-cost option to the patients, therefore particularly, in the developing regions the adoption of EPO drugs have increased.
Based on product type erythropoietin stimulating agent can divided as Epoetin-alfa, Epoetin-beta, epoetin omega, epoetin delta and darbepoetin-alpha. Application of erythropoietin stimulating agents are classified as anemia, cancer chemotherapy, kidney disorders (ESRD and dialysis), antiretroviral treatment (ART) and others (neural disease and wound healing),
Some of the major players in erythropoietin stimulating agent market are Amgen Inc., Biocon, Celltrion, Inc., Hospira Inc., Intas Pharmaceuticals, Johnson & Johnson, Ranbaxy Laboratories Ltd., Roche, LG Life Sciences Ltd. and Teva Pharmaceutical Industries Ltd.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.